← Back to companies
Savara
0 open
Austin, Texas, United StatesFounded 200764+ employees$746.8M raisedIPOSVRA
Last round: post ipo debt · $75M · Jan 2026(18 rounds total)
⚠1 layoff event · Last: Dec 2020
Founded by Chris Marich, Rob Neville, Taneli Jouhikainen
Backed by(22 investors)
Hercules CapitalRTW InvestmentsBain Capital Life SciencesCystic Fibrosis FoundationHaas PortmanKeiretsu Forum Mid AtlanticSilicon Valley BankFirst Light Asset ManagementNantahala Capital ManagementWellington ManagementFrazier Life SciencesTCG CrossoverFarallon Capital ManagementNew Enterprise Associates
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. More information on the Phase 3 IMPALA-2 clinical trial in aPAP can be found at www.impala2.com
Open Positions at Savara (0 Jobs)
No open positions at the moment.
Browse All JobsReady to start your space career at Savara?
